Adopted Trials - Pancreatic
Acronym: MetXia
Full Title
Study of Safety and Efficacy of MetXia-OB83 and Cyclophosphamide in Patients Undergoing Palliative Surgery for Adenocarcinoma of the Head of the Pancreas
Treatment: Immunological (immunotherapy & gene therapy)
Phase: 1/2
Current status: Completed and closed down
Chief Investigator: Prof J P Neoptolemos
Type of trial: New Technologies
Acronym: KAbI
Full Title
An open, randomised phase I/II dose escalation study evaluating the safety and tolerability, pharmacokinetics, antigenicity and efficacy of Iodine-131-Kab201 when given intra-arterially or intravenously in patients with surgically unresectable pancreatic ductal adenocarcinoma (KSB303PAN/CI/001)
Treatment: Simple antibodies (indirect & direct acting)
Phase: 1/2
Current status: Completed and closed down
Chief Investigator: Prof J P Neoptolemos
Type of trial: New Technologies
Website:
Acronym: ESPAC-1
Full Title
A European, randomised study to assess the roles of adjuvant chemotherapy (5FU+Folinic Acid) and adjuvant chemoradiation (40GY+5FU) in resectable pancreatic cancer
Treatment: Chemotherapy
Phase: 3
Current status: Completed and closed down
Chief Investigator: Prof J P Neoptolemos
Type of trial: Biomarkers
Acronym: ESPAC-3(v2)
Full Title
Phase III adjuvant trial in pancreatic cancer comparing 5-fluorouracil plus DL folinic acid with gemcitabine or no adjuvant treatment (ESPAC3 V2)
Treatment: Chemotherapy
Phase: 3
Current status: Closed to recruitment - in follow-up
Chief Investigator: Prof J P Neoptolemos
Type of trial: Biomarkers
Acronym: TeloVac
Full Title
A prospective, phase III, controlled, multicentre, randomised clinical trial comparing Gemcitabine and Capecitabine therapy with concurrent and sequential chemoimmunotherapy using a telomerase vaccine in locally advanced and metastatic pancreatic cancer
Treatment: Immunological (immunotherapy & gene therapy)
Phase: 3
Current status: Open to recruitment
Chief Investigator: Dr Gary Middleton
Type of trial: Biomarkers
Acronym: CytImmune
Full Title
A phase I/II dose finding early efficacy study of cyt-6091 in combination with Gemcitabine in patients with advanced pancreatic cancer
Treatment: Other complex biological therapies
Phase: 1/2
Current status: On hold
Chief Investigator: Dr David Smith
Type of trial: Early Phase
Website:
Acronym: ESPAC-4
Full Title
European Study Group for Pancreatic Cancer (ESPAC) -Trial 4. Combination versus single agent adjuvant chemotherapy in resectable pancreatic cancer.
Treatment: Chemotherapy
Phase: 3
Current status: Open to recruitment
Chief Investigator: Prof J P Neoptolemos
Type of trial: Biomarkers
Website:
Acronym: PERU
Full Title
A multicentre randomised phase II clinical study of UFT/leucovorin, radiotherapy with or without cetuximab following induction gemcitabine plus capecitabine in patients with locally advanced pancreatic cancer (Pancreatic cancer Erbitux, Radiotherapy and UFT/leucovorin)
Treatment: Chemotherapy
Phase: 2
Current status: In set-up
Chief Investigator: Dr Ian Chau
Type of trial: Early Phase
Website:
Acronym: VIP
Full Title
A prospective, phase II, controlled, multicentre, randomised clinical trial comapring combination gemcitabine and vandetanib therapy with gemcitabine therapy alone in advanced pancreatic cancer.
Treatment: Chemotherapy
Phase: 2
Current status: In set-up
Chief Investigator: Dr Gary Middleton
Type of trial: Early Phase
Website:
